Anixa Biosciences reaches maximum tolerated dose in Phase 1a trial of breast cancer vaccine

Anixa Biosciences Inc

Maximum tolerated dose achieved in Phase 1a trial of preventative breast cancer vaccine.
Vaccine developed in collaboration with Cleveland Clinic.
Results presented at San Antonio Breast Cancer Symposium; press release and poster furnished.

item 7.01 item 9.01

Anixa Biosciences Inc filing history →

Source: SEC EDGAR

accession 0001493152-22-034828

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.